{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T03:24:23Z","timestamp":1790652263751,"version":"4.1.0"},"reference-count":0,"publisher":"American Society of Hematology","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:p>Chimeric antigen receptor (CAR)-T cells have transformed the care of patients with hematologic malignancies. Patients treated with CAR-T cells may experience cardiovascular and pulmonary complications which primarily occur in the setting of cytokine release syndrome. In addition, many patients considered for CAR-T cell therapy have pre-existing cardiac and pulmonary comorbidities. In patients with good functional status, these conditions should not prevent patients from being offered these life-saving therapies. In this \"How I Treat\" article, we use a case-based approach to discuss how we evaluate and optimize patients with cardiac and pulmonary risk factors prior to CAR-T cell therapy and how we manage cardiac and pulmonary complications that may arise with treatment.<\/jats:p>","DOI":"10.1182\/blood.2022017579","type":"journal-article","created":{"date-parts":[[2023,2,24]],"date-time":"2023-02-24T20:57:48Z","timestamp":1677272268000},"update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":11,"title":["How I approach optimization of patients at risk of cardiac and pulmonary complication after CAR-T cell therapy"],"prefix":"10.1182","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6381-6216","authenticated-orcid":false,"given":"Cristina","family":"Gutierrez","sequence":"first","affiliation":[{"name":"MD Anderson Cancer Center, Houston, Texas, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomas","family":"Neilan","sequence":"additional","affiliation":[{"name":"Massachusetts General Hospital, Boston, Massachusetts, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1346-3157","authenticated-orcid":false,"given":"Natalie S.","family":"Grover","sequence":"additional","affiliation":[{"name":"University of North Carolina, Chapel Hill, North Carolina, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2023,2,24]]},"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/doi\/10.1182\/blood.2022017579\/2035940\/blood.2022017579.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/doi\/10.1182\/blood.2022017579\/2035940\/blood.2022017579.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,24]],"date-time":"2023-02-24T20:58:09Z","timestamp":1677272289000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/doi\/10.1182\/blood.2022017579\/494701\/How-I-approach-optimization-of-patients-at-risk-of"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,24]]},"references-count":0,"URL":"https:\/\/doi.org\/10.1182\/blood.2022017579","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,24]]},"article-number":"blood.2022017579"}}